Effect of sucralfate on aspirin induced mucosal injury and impaired haemostasis in humans

N Hudson, F E Murray, A T Cole, B Filipowicz, C J Hawkey

Abstract

Background—Sucralfate does not have potent anti-ulcerogenic actions in users of non-steroidal anti-inflammatory drugs (NSAIDs). However, sucralfate may influence intra gastric haemostasis favourably.

Aim—To investigate separately the effects of sucralfate on acute gastric and duodenal injury and on changes in intragastric bleeding induced by aspirin.

Method—On three occasions, 24 healthy volunteers received three days' treatment with aspirin 900 mg twice daily together with placebo, sucralfate 2 g twice daily or sucralfate 1 g four times daily. Injury was assessed endoscopically and bleeding by spontaneous and biopsy induced bleeding intra gastric washings. Ex vivo prostaglandin E_2 (PGE_2) synthesis and serum thromboxane were measured by using radioimmunoassay.

Results—Aspirin significantly inhibited ex vivo gastric mucosal PGE_2 synthesis, reduced serum thromboxane, caused gastric erosions, and increased spontaneous and biopsy induced bleeding. Sucralfate had no significant effects on endoscopic injury but sucralfate 1 g four times daily significantly reduced spontaneous and biopsy induced bleeding. Similar trends were seen with sucralfate 2 g twice daily but the results were less consistent.

Conclusion—Sucralfate does not affect aspirin induced acute gastric mucosal injury but reduces aspirin associated intra gastric bleeding.

(Gut 1997; 41: 19–23)

Keywords: aspirin; non-steroidal anti-inflammatory drug; sucralfate; ulcer; haemostasis; protection activity. This action may contribute to sucralfate's established well known ability to prevent stress induced gastric bleeding.

As, in these circumstances, sucralfate's predominant intra gastric action may be on haemostasis rather than ulceration, we investigated its effects on acute aspirin induced intra gastric mucosal erosions, mucosal damage and bleeding to see whether these effects could be differentiated.

Methods

This was a double blind, placebo controlled, crossover comparison with randomisation according to Latin square design. Each treatment period was of three days duration with a washout period between treatments of 11 days. Our previous studies have shown that erosions heal within two to three days and an 11 day washout period is associated with no carry over effects attributable to the previous treatment. Each subject received, under blinded, randomised conditions, each of the following dosage regimens: aspirin 900 mg twice daily with placebo; aspirin 900 mg twice daily with sucralfate 2 g twice daily; aspirin 900 mg twice daily with sucralfate 1 g four times daily.

Subjects

Twenty four healthy volunteers were studied. The main exclusion criteria included hypersensitivity to aspirin, presence or history of peptic ulceration or significant dyspepsia, history of easy bruising or bleeding, bleeding abnormality detected during initial screening, anaemia, history of asthma, lactation, pregnancy, or unacceptable contraception.

Study procedures

Subjects underwent a medical examination, with haematological/biochemical screening up to two weeks before the start of the study. During the study the following procedures were done before dosing and on day 3 of each dosing period.

GASTRIC MICROBLEEDING

Fasted subjects swallowed an orogastric tube at approximately 0800 hours of each study day, 90 minutes after taking the last dose of aspirin with water. One hundred millilitres of water was introduced through the orogastric tube, rinsed around the stomach (see later) and then drained. This procedure was repeated three times. Three 10 minute collection periods then commenced and at the end of each period the
stomach was washed with 100 ml water. Phenol red was used to measure recovery and the stomach was rinsed twice after each wash to remove phenol red before the next collection period. Whenever liquids were introduced into the stomach, each volunteer performed a series of manoeuvres designed to ensure contact of the liquid with all parts of the stomach. Blood in the gastric washings was measured spectrophotometrically using the orthotolidine reaction, and corrected for phenol red recovery.

**ENDOSCOPIC ASSESSMENT OF INJURY**
Immediately after gastric washing for microbleeding was complete, the orogastric tube was removed and the volunteers underwent unsedated endoscopy with a 7-9 mm diameter XP endoscope. Erosions in the oesophagus, gastric body, gastric antrum, and duodenum were counted separately. Endoscopic assessment was performed rapidly in order to minimise the time between assessment of microbleeding and collection of washings for the assessment of biopsy induced bleeding (see later). Although four endoscopists participated in the study, each studied their own cohort of volunteers. Previous studies from our unit have, however, shown a close interindividual correlation ($r=0.85$) in the endoscopic assessment of acute injury.

**BLEEDING PER EROSION**
This value was derived in subjects found to have erosions at endoscopy by dividing the overall rate of gastric microbleeding by the total number of erosions seen in the stomach (body and antrum aggregated).

**BIOPSY INDUCED BLEEDING RATES**
At the end of the endoscopy, four mucosal biopsy specimens were taken from the greater curve at approximately 50 cm from the teeth using a standard 2 mm cup biopsy forceps. The endoscope was withdrawn and subjects were immediately intubated with a prepared orogastric tube. The gastric mucosa was washed with 100 ml water five minutes after mucosal biopsy and again after a further five minutes. During this time subjects lay rocking on their left hand side only so that the bleeding biopsy site was selectively washed. The recovered blood was measured using the orthotolidine reaction, and corrected for spontaneous mucosal bleeding as described previously.

**EICOSANOIDs**
The four biopsy specimens were divided into pairs and washed in Tris buffered saline (TBS). Each pair of biopsy specimens was then vortexed in 500 µl TBS for one minute at room temperature. The biopsy specimens were then removed and weighed, and the supernatant stored at −70°C until assay. Prostaglandin $E_2$ (PGE$_2$) in the unextracted supernatant was measured using specific radioimmunoassays. PGE$_2$ was expressed as pg/mg wet weight of gastric mucosa.

**SERUM THROMBOXANE**
This was assayed in 12 of the subjects. Immediately after endoscopy, 10 ml blood was taken and allowed to clot for 30 minutes at 37°C. Serum thromboxane was measured in separated serum from these samples using a radioimmunoassay.

**STATISTICS AND POWER**
Analysis of variance was used to identify statistically significant differences. Bleeding values – basal microbleeding, bleeding per erosion and biopsy induced bleeding – as well as the number of lesions detected endoscopically tend to have a skewed distribution which approximates to normal after logarithmic transformation. The data were analysed in their logarithmic form. For analyses involving numbers of lesions, subjects with no detectable lesions were regarded as having 0·5 lesions to allow an analysis in this way. Based upon previous data, the present study was designed to have the power to detect a reduction in microbleeding from 10 µl/10 minutes to 5-6 µl/10 minutes ($\beta=0.8$) or 5-1 µl/10 minutes ($\beta=0.9$), based upon two-tailed testing and $\alpha=0.05$.

**RESULTS**

**SUBJECTS**
Twenty four volunteers were enrolled into the study. Twenty three completed all study periods successfully and formed the basis of the analysis. One subject had food in the stomach preventing visualisation at the final assessment: all data from this subject were excluded from analysis.

**GASTRIC MUCOSAL SYNTHESIS OF PROSTAGLANDIN $E_2$**
There was a significant inhibition of ex vivo gastric mucosal PGE$_2$ synthesis (p<0.001) when aspirin was given over the three day period (table 1). Sucralfate did not seem to attenuate this reduction in PGE$_2$ synthesis associated with aspirin. There was no significant difference in gastric mucosal PGE$_2$ synthesis rates between the three treatment arms.

**TABLE 1** Gastric mucosal synthesis of prostaglandin $E_2$ before and after treatment with aspirin and aspirin plus sucralfate

<table>
<thead>
<tr>
<th>Prostaglandin $E_2$ (pg/mg)</th>
<th>Baseline</th>
<th>Final</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>22·9 (15·9–37·9)</td>
<td>3·2*** (1·6–6·2)</td>
</tr>
<tr>
<td>Aspirin+sucralfate (1 g qid)</td>
<td>17·8 (11·5–27·5)</td>
<td>3·7*** (2·0–7·0)</td>
</tr>
<tr>
<td>Aspirin+sucralfate (2 g bid)</td>
<td>14·1 (9·0–19·8)</td>
<td>4·0*** (2·3–6·8)</td>
</tr>
</tbody>
</table>

***p<0.001 compared with baseline. qid=for times a day, bid=twice a day.
SERUM THROMBOXANE

These changes in mucosal PGE2 synthesis were reflected by similar changes in the serum thromboxane concentrations (table 2). Thus, at baseline before ingestion of aspirin serum thromboxane was 9·1 (6·8–12·2) ng/ml and fell to essentially unrecordable concentrations after treatment with aspirin or placebo (p<0·001). Co-administration of sucralfate did not affect this reduction in serum thromboxane.

MUCOSAL EROSIONS

Gastric erosions

None of the subjects had any erosions before any of the treatment periods. After three days of aspirin treatment this rose significantly to 5·3 (2·9–9·4) erosions throughout the stomach (p<0·001; table 3). Sucralfate did not significantly affect the number of erosions after aspirin treatment. Likewise, the distribution between antrum and body was not affected by sucralfate treatment.

Duodenal erosions

Duodenal damage with all three regimens was infrequent. There was no significant difference in the number of erosions in the duodenum when aspirin was co-administered with either sucralfate 1 g four times daily or 2 g twice daily compared with aspirin with placebo.

BLEEDING PARAMETERS

Validation

In initial experiments, addition of sucralfate suspension to gastric juice in concentrations from 0 to 5% (v/v) did not affect the quantitative assay of blood recovered ex vivo. Similarly, blood added to gastric aspirates was measured accurately and quantitatively whether sucralfate was added or not.

**TABLE 2** Serum thromboxane concentrations before and after treatment with aspirin and aspirin plus sucralfate

<table>
<thead>
<tr>
<th>Serum thromboxane (ng/ml)</th>
<th>Baseline</th>
<th>Final</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>9·1 (6·8–12·2)</td>
<td>0·05*** (0·05–0·05)</td>
</tr>
<tr>
<td>Aspirin+sucralfate (1 g qid)</td>
<td>8·3 (5·8–11·4)</td>
<td>0·05*** (0·05–0·05)</td>
</tr>
<tr>
<td>Aspirin+sucralfate (2 bid)</td>
<td>5·62 (1·6–19·8)</td>
<td>0·10*** (0·03–0·34)</td>
</tr>
</tbody>
</table>

***p<0·001 compared with baseline. qid=four times a day; bid=twice a day.

**TABLE 3** Gastric mucosal erosions before and after treatment with aspirin and aspirin and sucralfate

<table>
<thead>
<tr>
<th>Gastric mucosal erosions</th>
<th>Baseline</th>
<th>Final</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>0</td>
<td>5·3*** (2·9–9·4)</td>
</tr>
<tr>
<td>Aspirin+sucralfate (1 g qid)</td>
<td>0</td>
<td>4·2*** (2·1–8·2)</td>
</tr>
<tr>
<td>Aspirin+sucralfate (2 bid)</td>
<td>0</td>
<td>6·9*** (3·5–13·6)</td>
</tr>
</tbody>
</table>

***p<0·001 compared with baseline. qid=four times a day; bid=twice a day.

Microbleeding

After aspirin with placebo, the median rate of gastric microbleeding rose by a factor of 13·8 (95% confidence interval (CI) 7·8–24·5, p=0·001 compared with baseline) from 1·6 (1·1–2·3) μl per 10 minutes to 24·6 (15·9–37·9) μl per 10 minutes (table 4). There were also significant increases, by factors respectively of 5·1 (2·9–9·1) and 5·8 (3·2–10·2) with the two sucralfate regimens. However, analysis of variance showed that there were significant differences between the three treatments for absolute bleeding values on day 3 (p<0·05) and for the rise from baseline (p<0·05). Pairwise comparisons showed that the rise with aspirin plus sucralfate 1 g four times daily was significantly less than for aspirin with placebo (p=0·037, paired t test). When the absolute final value of microbleeding for aspirin plus sucralfate 1 g four times daily (10·5 μl, 95% CI 5·9–18·7 μl) was compared with the absolute final value for aspirin (24·6 μl, 95% CI 15·9–37·9 μl), this was significantly reduced (p=0·018). For aspirin with sucralfate 2 g twice daily, pairwise comparisons also showed reduced spontaneous bleeding compared with aspirin plus placebo. These differences were at borderline levels of statistical significance for the increase in microbleeding (p=0·052) and the absolute final value of 12·9 (6·6–25·4) μl per 10 minutes (p=0·08).

Biopsy induced bleeding

There was a significant increase in the amount of biopsy induced bleeding over five and 10 minutes when aspirin was administered with placebo (p<0·01; table 5). There was no significant increase for any of these values when aspirin was administered with sucralfate 1 g four times daily. However, bleeding did seem
to increase (p=0.01) when aspirin was administered with sucralfate 2 g twice daily.

**Bleeding per erosion**

Twelve subjects had erosions at the final endoscopy for all treatment periods. For these subjects, it was possible to calculate a value for spontaneous microbleeding per erosion (table 6). This fell from 2.57 (1.0-3-6.40) μl per erosion with aspirin plus placebo to 1.02 (0.37-2.81) μl per erosion when aspirin was co-administered with sucralfate 1 g four times daily (p=0.065), and 1.05 (0.46-2.36) μl per erosion when aspirin was co-administered with sucralfate 2 g twice daily (p=0.072).

**Discussion**

In this study the effects of aspirin on PGE₂, thromboxane, erosions, and bleeding are very similar to those observed in previous studies of similar design and duration conducted in this department. These studies have established the validity of the method. They have shown that assessment of the number of erosions is reproducible between individual endoscopists. Moreover, each endoscopist studied a cohort of volunteers to improve the reproducibility of repeated measurements. Our previous studies have also shown that the washout period used in this study is sufficient for erosions to heal, for the serum thromboxane concentration to return to normal, and for intra-gastric bleeding to be uninfluenced by treatment order. In the present study we found that sucralfate had no significant protective effects against the development of gastric erosions, but that several of our measures of intra-gastric bleeding were favourably influenced. Thus, aspirin caused significant increases in microbleeding and in biopsy induced bleeding and these, along with the amount of bleeding per erosion, were significantly reduced when sucralfate 1 g four times daily was co-administered with aspirin. Sucralfate 2 g twice daily also showed a trend towards a reduction in spontaneous microbleeding and in bleeding per erosion, although these were both at borderline levels of significance. Sucralfate 2 g twice daily did not, however, abrogate the increase in biopsy induced bleeding seen with aspirin. The reason for this discrepancy between the two sucralfate dosing regimens is not clear. Overall, however, our results suggest that sucralfate has a direct effect on intra-gastric haemostasis.

Bleeding is a balance between clot formation and clot lysis. Fibrinolysis is a two stage process initiated by formation of fibrin and is evident within one to three minutes. Clot lysis seems to be particularly important in relation to intra-gastric bleeding as it is strongly activated by gastric juice via a proteolytic and a plasminogen dependent pathway. Sucralfate brings about profound reductions in both proteolysis and plasmin mediated fibrinolysis, and it seems likely that these actions also underlie our results. Given a one to three minute delay in activation of detectable fibrinolysis, it is also possible that suppression of biopsy induced bleeding by sucralfate would be more evident at later time points.

Sucralfate is widely used in the prophylaxis of stress ulceration in patients on intensive care units. A direct effect on intra-gastric bleeding rather than any primary anti-erosive effects may underlie this therapeutic efficacy. In most studies bleeding has been used as an end point rather than direct endoscopic mucosal assessment. Whether sucralfate reduces stress induced erosions compared with placebo or H₂-receptor antagonists is controversial with discrepancies between different studies. It is also controversial whether H₂-receptor antagonists or misoprostol will prevent the development of erosions by an anti-erosive effect. Thus, for both sucralfate and H₂-receptor antagonists an effect on intra-gastric bleeding rather than on mucosal erosion may be important when used in a prophylaxis of stress associated bleeding. Whether the same applies to prophylaxis by sucralfate and H₂-receptor antagonists of NSAID associated ulcers cannot be determined directly. However, this too is possible as indirect evidence suggests that H₂-receptor antagonists have a greater effect on recurrence of ulcer bleeding than uncomplicated ulceration, implying an additional effect on haemostasis. Our data raise the possibility that sucralfate could likewise prevent NSAID associated bleeding complications, by direct effect on haemostasis, rather than an anti-erosive one.

Although these results were obtained in volunteers in the short term with aspirin, this approach is predictive of the behaviour of prostaglandin analogues and of acid suppressing drugs in clinical practice. In short term studies prostaglandins have proved to be protective for both the stomach and duodenum and the same is true of long term prevention of ulceration. Normal doses of H₂-receptor antagonists, by contrast, only exert significant protection in the duodenum both in the short term studies with aspirin and long term studies with NSAIDs. Our data, therefore, suggest that sucralfate would not have a significant ability to prevent NSAID associated ulcers in the long term. One study which compared sucralfate with misoprostol showed little efficacy in prevention of ulcers detected endoscopically. The predictive value of the effects of sucralfate on haemostasis that we have shown is less easy to determine. However, we have shown that acid suppression specifically reduces intra-gastric bleeding in the short term, and several authors have shown that relapse with ulcer bleeding in the long

### Table 6: Bleeding per erosion before and after treatment with aspirin and aspirin plus sucralfate

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Baseline (μl)</th>
<th>Final (μl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>2.57</td>
<td>1.02</td>
</tr>
<tr>
<td>Aspirin+sucralfate (1 g qid)</td>
<td>1.02 (0.37-2.81)</td>
<td>1.05 (0.46-2.36)</td>
</tr>
<tr>
<td>Aspirin+sucralfate (2 g bid)</td>
<td>1.05 (0.46-2.36)</td>
<td>1.05 (0.46-2.36)</td>
</tr>
</tbody>
</table>

*p=0.065; **p=0.072.

qid=four times a day; bid=twice a day.
term is reduced to a greater extent than uncomplicated relapse. It is possible that sucralfate could reduce the incidence of NSAID induced haematemesis and melena without reducing the development of ulcers, although it would be a formidable proposition to demonstrate this directly.

We thank Miss Donna Hall, Miss Claire Spencer and Mrs Rosemary Dainty for preparation of the manuscript, and Chugai for their financial support and for supplying sucralfate.

Effect of sucralfate on aspirin induced mucosal injury and impaired haemostasis in humans.
N Hudson, F E Murray, A T Cole, B Filipowicz and C J Hawkey

Gut 1997 41: 19-23
doi: 10.1136/gut.41.1.19

Updated information and services can be found at:
http://gut.bmj.com/content/41/1/19

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/